Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 4, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2021.

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

Pasadena. CA | Posted on April 16th, 2021

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm . For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 3080187.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 3080187.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “plan,” “project,” “could,” “estimate,” or “continue” are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our businesses, or other characterizations of future events or circumstances are forward-looking statements. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the continuing impact of the COVID-19 pandemic, the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361

www.lifescicommunications.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Optimized method to detect high-dimensional entanglement December 3rd, 2021

Scientists edge closer to probe that would inspect atherosclerotic plaques by forcing molecules to sound their presence December 3rd, 2021

Two-dimensional bipolar magnetic semiconductors with high Curie-temperature and electrically controllable spin polarization realized in exfoliated Cr(pyrazine)2 monolayers December 3rd, 2021

Review on the femtosecond laser precision micro/nano-engineering December 3rd, 2021

Nanomedicine

Scientists edge closer to probe that would inspect atherosclerotic plaques by forcing molecules to sound their presence December 3rd, 2021

Immune system-stimulating nanoparticle could lead to more powerful vaccines: The potent new adjuvant could be used to help make vaccines against HIV and other infectious diseases December 3rd, 2021

Scientists develop promising vaccine method against recurrent UTI November 19th, 2021

Cancer cells use ‘tiny tentacles’ to suppress the immune system: With the power of nanotechnology, investigators have discovered that cancer cells strengthen by forming nanotubes that they use to suck mitochondria out of immune cells November 19th, 2021

Announcements

Scientists edge closer to probe that would inspect atherosclerotic plaques by forcing molecules to sound their presence December 3rd, 2021

Two-dimensional bipolar magnetic semiconductors with high Curie-temperature and electrically controllable spin polarization realized in exfoliated Cr(pyrazine)2 monolayers December 3rd, 2021

Review on the femtosecond laser precision micro/nano-engineering December 3rd, 2021

Development of a single-process platform for the manufacture of graphene quantum dots: Precisely controls the bonding configuration of heteroatoms in graphene quantum dots through simple chemical processes. Practical application and commercialization in various fields is expected December 3rd, 2021

Financial Reports

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

180 Degree Capital Corp. to Report Fourth Quarter 2020 Financial Results on Monday, February 22, 2021 and to Host a Conference Call on Tuesday, February 23, 2021 February 19th, 2021

Events/Classes

Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences September 1st, 2021

UVA Engineering researchers join quest to demonstrate photonic systems-on-chip: Future applications include faster, more efficient data centers and next-generation millimeter-wave wireless communication July 30th, 2021

Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress June 25th, 2021

Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress June 24th, 2021

Nanobiotechnology

Scientists edge closer to probe that would inspect atherosclerotic plaques by forcing molecules to sound their presence December 3rd, 2021

Immune system-stimulating nanoparticle could lead to more powerful vaccines: The potent new adjuvant could be used to help make vaccines against HIV and other infectious diseases December 3rd, 2021

Scientists develop promising vaccine method against recurrent UTI November 19th, 2021

Cancer cells use ‘tiny tentacles’ to suppress the immune system: With the power of nanotechnology, investigators have discovered that cancer cells strengthen by forming nanotubes that they use to suck mitochondria out of immune cells November 19th, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project